Triazolone compounds and uses thereof
The invention disclosed herein is directed to compounds of Formula I and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.
1. A method for treating cancer comprising administering a therapeutically effective amount of a compound of Formula I, to a mammal in need thereof:
or a pharmaceutically acceptable salt thereof, wherein:
A1 is phenyl, pyrimidinyl, or pyridinyl;
A2 is A2a
wherein A2a is phenyl or pyridinyl;
X is selected from the group consisting of —(CH 2 ) 2 —, —(CH 2 ) 3 —, or —(CH 2 ) 4 —, each optionally mono- or di-substituted with halogen;
Y is O;
R 1 and R 2 are each independently selected from the group consisting of:
(a) hydrogen,
(b) halogen,
(c) —O—(R 7 ),
(d) CF 3 ,
(e) —C 1-6 alkyl,
R 3 is selected from the group consisting of:
(a) hydrogen,
(b) —C 1-6 alkyl,
(c) —O—(R 7 ), and
(d) —N(R 7 )S(═O) 2 (R 8 ),
wherein the alkyl portion of choice (b) is optionally substituted with halogen or hydroxyl;
R 4 and R 4′ are each independently selected from the group consisting of:
(a) hydrogen,
(b) —O—R 7 ,
(c) —C(R 7 )(R 8 )OH,
(d) —C 1-6 alkyl-C(═O)OH,
(e) —C 3-6 cycloalkyl-C(═O)OH,
(f) —C(═O)OH,
(g) —NHS(═O) 2 N(R 7 )(R 8 ),
(h) —C 3-6 cycloalkyl,
(i) —CF 3 ,
(j) -heterocycle,
(k) —C 1-6 alkyl, and
(l) halogen;
with the proviso that at least one of R 3 , R 4 and R 4′ is other than hydrogen;
R 5 is selected from the group consisting of:
(a) hydrogen,
(b) —C 1-6 alkyl,
(c) —C 1-4 alkyl(R 7 ),
wherein the alkyl portion of choices (b) and (c) is optionally substituted with halogen or C 1-4 alkyl;
R 6 is selected from the group consisting of:
(a) —C 1-6 alkylaryl,
(b) —C 1-6 alkylheteroaryl, and
(c) C 1-4 alkyl(R 7 );
wherein the alkyl portion of choices (a), (b), and (c) is optionally substituted with halogen or C 1-4 alkyl, and
wherein the aryl portion of choice (a), and the heteroaryl portion of choice (b) are optionally mono- or di-substituted with substituents selected from the group consisting of halogen, nitro, —CF 3 , C 1-6 alkyl, C 1-6 alkoxy, halo C 1-6 alkyl, C 3-6 cycloalkyl, C 3-6 cycloalkoxy, aryl, heteroaryl, heterocycle optionally substituted with halogen, —NH(C 1-6 alkyl), —NH(C 3-6 cycloalkyl), —N(C 1-6 alkyl) 2 , —N(C 3-6 cycloalkyl) 2 , —S(═O) o C 1-6 alkyl, S(═O) o C 3-6 cycloalkyl, and CN, wherein each o is independently 0,1, or 2;
R 7 and R 8 are each independently selected from the group consisting of:
(a) hydrogen,
(b) —C 1-6 alkyl,
(c) —C 3-6 cycloalkyl,
(d) -aryl,
(e) -heteroaryl, and
(f) CF 3 ; and
R 9 and R 10 are each independently selected from the group consisting of:
(a) hydrogen,
(b) —C 1-6 alkyl,
(c) halogen,
(d) CF 3 , and
(e) C 1-6 alkoxy
wherein the alkyl of choice (b) is optionally mono-, di- or tri-substituted with halogen,
wherein the cancer is selected from the group consisting of prostate cancer, breast cancer, ovarian cancer, liver cancer, kidney cancer, colon cancer, pancreatic cancer, human chronic lymphocytic leukemia, and melanoma.
2. The method according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein X is —CH 2 CH 2 CH 2 — or —CF 2 CH 2 CH 2 —.
3. The method according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein: A1 is phenyl, and R 1 and R 2 are each hydrogen.
4. The method according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein: A2 is A2a and A2a is phenyl.
5. The method according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein: R 3 is selected from the group consisting of:
(a) hydrogen,
(b) —O—(R),
(c) —N(R 7 )S(═O) 2 (R), and
(d) —C 1-6 alkyl; and
R 4 and R 4′ are each independently selected from the group consisting of:
(a) hydrogen,
(b) —O—(R),
(c) —C(R 7 )(R 8 )OH,
(d) —C 1-6 alkyl-C(═O)OH,
(e) —C 3-6 cycloalkyl-C(═O)OH,
(f) —C(═O)OH,
(g) C 3-6 cycloalkyl,
(h) CF 3 ,
(i) heterocycle,
(j) —C 1-6 alkyl, and
(k) halogen.
6. The method according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein:
R 4 and R 4′ are each independently selected from the group consisting of:
(a) —C(R 7 )(R 8 )OH,
(b) —O—(R),
(c) —C 1-6 alkyl-C(═O)OH,
(d) —C(═O)OH,
(e) —C 3-6 cycloalkyl,
(f) CF 3 ,
(g) heterocycle,
(h) —C 1-6 alkyl, and
(i) halogen;
R 5 is selected from the group consisting of:
(a) hydrogen,
(b) —C 1-6 alkyl, and
(c) —C 1-4 alkyl(R); and
R 6 is selected from the group consisting of:
(a) —C 1-6 alkylaryl,
(b) —C 1-6 alkylheteroaryl, and
(c) —C 1-6 alkyl(R); and
wherein the aryl portion of choice (a), and the heteroaryl portion of choice (b) are optionally mono- or di-substituted with substituents selected from the group consisting of halogen, nitro, —CF 3 , C 1-6 alkyl, C 1-6 alkoxy, halo C 1-6 alkyl, C 3-6 cycloalkyl, C 3-6 cycloalkoxy, aryl, heteroaryl, heterocycle optionally substituted with halogen, —NH(C 1-6 alkyl), —NH(C 3-6 cycloalkyl), —N(C 1-6 alkyl) 2 , —N(C 3-6 cycloalkyl) 2 , and CN.
7. The method according to claim 1 , wherein the compound is a compound of Formula 1b:
or a pharmaceutically acceptable salt thereof.
8. The method of claim 1 , wherein the cancer is selected from the group consisting of prostate cancer, breast cancer, and ovarian cancer.
9. The method of claim 1 , wherein the cancer is selected from the group consisting of liver cancer, kidney cancer, and colon cancer.
10. The method of claim 1 , wherein the cancer is selected from the group consisting of human chronic lymphocytic leukemia and melanoma.
11. The method of claim 1 , wherein the cancer is pancreatic cancer.
12. A method for treating cancer comprising administering a therapeutically effective amount of a compound selected from:
2-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-3-yl)acetic acid,
2-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-4-yl)acetic acid,
3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)[1,1′-biphenyl]-3-carboxylic acid,
3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)[1,1′-biphenyl]-4-carboxylic acid,
1-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-ethoxy-[1,1′-biphenyl]-3-yl)cyclopropanecarboxylic acid,
2-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-ethoxy-[1,1′-biphenyl]-3-yl)acetic acid,
1-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-3-yl)cyclopropanecarboxylic acid,
1-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-4-yl)cyclopropanecarboxylic acid,
3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-methoxy-[1,1′-biphenyl]-3-carboxylic acid,
3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-ethoxy-[1,1′-biphenyl]-3-carboxylic acid,
2-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-propoxy-[1,1′-biphenyl]-3-yl)acetic acid,
N-(6-(3-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)phenyl)pyridin-3-yl)benzenesulfonamide,
2-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-methoxy-[1,1′-biphenyl]-3-yl)acetic acid,
1-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-methyl-[1,1′-biphenyl]-3-yl)cyclopropanecarboxylic acid,
2-(4-(benzyloxy)-3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-3-yl)acetic acid,
2-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-(cyclopropylmethoxy)-[1,1′-biphenyl]-3-yl)acetic acid,
2-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-fluoro-[1,1′-biphenyl]-3-yl)acetic acid,
2-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-6-ethoxy-[1,1′-biphenyl]-3-yl)acetic acid,
3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-propoxy-[1,1′-biphenyl]-3-carboxylic acid,
N-((3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1′-biphenyl]-3-yl)methyl)benzenesulfonamide,
3-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-methoxy-[1,1′-biphenyl]-3-yl)propanoic acid,
2-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)-1,1-difluoropropyl)-4-ethoxy-[1,1′-biphenyl]-3-yl)acetic acid,
N-(6-(3-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)-1,1-difluoropropyl)phenyl)pyridin-3-yl)benzenesulfonamide,
2-(5-(6-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)pyridin-2-yl)-2-methoxyphenyl)acetic acid,
3-(3-(3′-(1H-tetrazol-5-yl)-[1,1′-biphenyl]-3-yl)propyl)-1-(4-(tert-butyl)benzyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one,
2-(5-(4-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)pyrimidin-2-yl)-2-ethoxyphenyl)acetic acid,
2-(5-(6-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)pyrimidin-4-yl)-2-ethoxyphenyl)acetic acid,
(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-3-methoxy-[1,1′-biphenyl]-4-yl)acetic acid,
(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-3-ethoxy-[1,1′-biphenyl]-4-yl)acetic acid,
(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-3-propoxy-[1,1′-biphenyl]-4-yl)acetic acid,
2-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-3-hydroxy-[1,1′-biphenyl]-4-yl)acetic acid,
2-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-isopropoxy-[1,1′-biphenyl]-3-yl)acetic acid, and
2-(3′-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-(2-(dimethylamino)ethoxy)-[1,1′-biphenyl]-3-yl)acetic acid,
or a pharmaceutically acceptable salt of any of the foregoing, to a mammal in need thereof,
wherein the cancer is selected from the group consisting of prostate cancer, breast cancer, ovarian cancer, liver cancer, kidney cancer, colon cancer, pancreatic cancer, human chronic lymphocytic leukemia, and melanoma.
13. The method of claim 12 , wherein the cancer is selected from the group consisting of prostate cancer, breast cancer, and ovarian cancer.
14. The method of claim 12 , wherein the cancer is pancreatic cancer.
15. The method of claim 12 , wherein the cancer is selected from the group consisting of liver cancer, colon cancer, and kidney cancer.
16. The method of claim 12 , wherein the cancer is human chronic lymphocytic leukemia or melanoma.
17. The method of claim 1 , wherein the compound has the structure:
18. The method of claim 7 , wherein the compound has the structure:
19. The method of claim 18 , wherein the compound has the structure:
20. The method of claim 18 , wherein the compound has the structure: